Literature DB >> 8843315

Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(--)-beta-L-2', 3'-dideoxy-3'-thiacytidine] in vitro.

K P Fischer1, D L Tyrrell.   

Abstract

Hepatitis B virus replication is very sensitive to lamivudine. A single amino acid change in human immunodeficiency virus reverse transcriptase is responsible for high-level resistance to this compound. Duck hepatitis B virus mutants were created bearing the analogous amino acid change in the duck hepatitis B virus polymerase. Viral DNA production was reduced 92% for the wild-type virus at 2 micrograms of lamivudine per ml, while the mutants required 40 micrograms of lamivudine per ml to inhibit replication by greater than 80%.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8843315      PMCID: PMC163451     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2',3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication.

Authors:  C N Chang; S L Doong; J H Zhou; J W Beach; L S Jeong; C K Chu; C H Tsai; Y C Cheng; D Liotta; R Schinazi
Journal:  J Biol Chem       Date:  1992-07-15       Impact factor: 5.157

2.  The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro.

Authors:  J A Coates; N Cammack; H J Jenkinson; I M Mutton; B A Pearson; R Storer; J M Cameron; C R Penn
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

3.  Mutations affecting hepadnavirus plus-strand DNA synthesis dissociate primer cleavage from translocation and reveal the origin of linear viral DNA.

Authors:  S Staprans; D D Loeb; D Ganem
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

4.  Mutation rate of the hepadnavirus genome.

Authors:  R Girones; R H Miller
Journal:  Virology       Date:  1989-06       Impact factor: 3.616

5.  Efficient duck hepatitis B virus production by an avian liver tumor cell line.

Authors:  L D Condreay; C E Aldrich; L Coates; W S Mason; T T Wu
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

6.  Nucleotide sequence of a cloned duck hepatitis B virus genome: comparison with woodchuck and human hepatitis B virus sequences.

Authors:  E Mandart; A Kay; F Galibert
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

7.  Biochemical pharmacology of (+)- and (-)-2',3'-dideoxy-3'-thiacytidine as anti-hepatitis B virus agents.

Authors:  C N Chang; V Skalski; J H Zhou; Y C Cheng
Journal:  J Biol Chem       Date:  1992-11-05       Impact factor: 5.157

8.  (-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro.

Authors:  J A Coates; N Cammack; H J Jenkinson; A J Jowett; M I Jowett; B A Pearson; C R Penn; P L Rouse; K C Viner; J M Cameron
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

9.  Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma.

Authors:  G J Hart; D C Orr; C R Penn; H T Figueiredo; N M Gray; R E Boehme; J M Cameron
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

10.  Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues.

Authors:  S L Doong; C H Tsai; R F Schinazi; D C Liotta; Y C Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

View more
  11 in total

1.  Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine.

Authors:  T Zhou; J Saputelli; C E Aldrich; M Deslauriers; L D Condreay; W S Mason
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication.

Authors:  William R Addison; Kathie-Anne Walters; Winnie W S Wong; John S Wilson; Danuta Madej; Lawrence D Jewell; D Lorne J Tyrrell
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

Review 3.  Treatment of chronic hepatitis B: new antiviral therapies.

Authors:  F Yao; R G Gish
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

4.  Humanized murine model for HBV and HCV using human induced pluripotent stem cells.

Authors:  Xiao-Ling Zhou; Gareth J Sullivan; Pingnan Sun; In-Hyun Park
Journal:  Arch Pharm Res       Date:  2012-02-28       Impact factor: 4.946

5.  Immunotargeting with CD154 (CD40 ligand) enhances DNA vaccine responses in ducks.

Authors:  Sheryl L Gares; Karl P Fischer; Stephen E Congly; Stacey Lacoste; William R Addison; D Lorne Tyrrell; Klaus S Gutfreund
Journal:  Clin Vaccine Immunol       Date:  2006-08

6.  Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus.

Authors:  V Thibault; Y Benhamou; C Seguret; M Bochet; C Katlama; F Bricaire; P Opolon; T Poynard; H Agut
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

7.  Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors.

Authors:  S K Ono-Nita; N Kato; Y Shiratori; K H Lan; H Yoshida; F J Carrilho; M Omata
Journal:  J Clin Invest       Date:  1999-06       Impact factor: 14.808

8.  Superinfection exclusion in duck hepatitis B virus infection is mediated by the large surface antigen.

Authors:  Kathie-Anne Walters; Michael A Joyce; William R Addison; Karl P Fischer; D Lorne J Tyrrell
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

9.  Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening.

Authors:  Kathie-Anne Walters; Graham A Tipples; Marchelle I Allen; Lynn D Condreay; William R Addison; Lorne Tyrrell
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

10.  Anti-hepatitis B virus activity and metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine.

Authors:  Y L Zhu; D E Dutschman; S H Liu; E G Bridges; Y C Cheng
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.